Biological Activity
Aripiprazole lauroxil, an N-acyloxymethyl prodrug of aripiprazole, is a Long-acting injectable (LAI) typical antipsychotic for schizophrenia. Aripiprazole lauroxil is cleaved by body’s enzyme esterase to N-hydroxymethyl aripiprazole (plus lauric acid) and then to aripiprazole (plus formaldehyde), no toxicity[1].
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
Aripiprazole lauroxil (intravenous administration; 1.87 mg/ml) bioconversion in vivo involves the formation of an intermediate, N-hydroxymethyl aripiprazole, the in vitro data indicates a high bioconversion of aripiprazole lauroxil, thus, the concentration of N-hydroxymethyl aripiprazole observed in the animals dosed with aripiprazole lauroxil is surprisingly high[1]. Animal Model: Female Sprague Dawley rats[1] Dosage: 1.87 mg/ml Administration: Blood samples is taken at 5, 15, 30 min and 1, 2, 4, 6, 8 and 24 h after administration Result: Exhibits an clearance: 0.32 ± 0.11 L/h/kg.
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
